# Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies

> **NCT03424603** · PHASE1 · COMPLETED · sponsor: **Sutro Biopharma, Inc.** · enrollment: 70 (actual)

## Conditions studied

- B-cell Lymphoma
- Non Hodgkin Lymphoma
- Multiple Myeloma
- Follicular Lymphoma
- Mantle Cell Lymphoma
- Diffuse Large B Cell Lymphoma
- Indolent Lymphoma
- B Cells--Tumors

## Interventions

- **DRUG:** STRO-001

## Key facts

- **NCT ID:** NCT03424603
- **Lead sponsor:** Sutro Biopharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-22
- **Primary completion:** 2024-02-15
- **Final completion:** 2024-03-15
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2024-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03424603

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03424603, "Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03424603. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*